Bibliografía

Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005 Oct 20;353(16):1652-1654.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 Jan 9;235(4785):177-182.
Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev 2001 Jun;27(3):137-142.
Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001 Sep;10(3):139-152.
Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers–a review. Gene 1995 Jun 14;159(1):19-27.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 May 12;244(4905):707-712.
Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994 May 15;54(10):2771-2777.
Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002 Jul 15;20(14):3095-3105.
Kay EW, Walsh CJ, Cassidy M, Curran B, Leader M. C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol 1994 Sep;47(9):816-822.
Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005 Sep 15;11(18):6598-6607.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007 Jan 1;25(1):118-145.
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013 Nov 1;31(31):3997-4013.
Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst 2012 Jan 18;104(2):159-162.
Polonia A, Leitao D, Schmitt F. Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment. Virchows Arch 2016 Apr;468(4):417-423.
Sapino A, Maletta F, Verdun di Cantogno L, Macri L, Botta C, Gugliotta P, et al. Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method. Oncologist 2014 Nov;19(11):1118-1126.
Fan YS, Casas CE, Peng J, Watkins M, Fan L, Chapman J, et al. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline. Breast Cancer Res Treat 2016 Feb;155(3):457-462.
Lim TH, Lim AS, Thike AA, Tien SL, Tan PH. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer. Arch Pathol Lab Med 2016 Feb;140(2):140-147.
Rakha EA, Pigera M, Shin SJ, D’Alfonso T, Ellis IO, Lee AHS. Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing? Histopathology 2016:n/a-n/a.
Varga Z, Noske A. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience. PLoS One 2015 Oct 16;10(10):e0140652.
Bethune GC, Veldhuijzen van Zanten D, MacIntosh RF, Rayson D, Younis T, Thompson K, et al. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as ‘equivocal’ for HER2 gene amplification by fluorescence in-situ hybridization. Histopathology 2015 Dec;67(6):880-887.
Muller KE, Marotti JD, Memoli VA, Wells WA, Tafe LJ. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry. Am J Clin Pathol 2015 Aug;144(2):247-252.
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013 Nov 1;31(31):3997-4013.
Solomon JP, Dell’Aquila M, Fadare O, Hasteh F. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization. Am J Clin Pathol. 2017 Apr 1;147(4):432-7.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977 Mar;33(1):159-74.
Li Z, Dabbs DJ, Cooper KL, Bhargava R. Dual HER2 gene protein assay: focused study of breast cancers with 2+ immunohistochemical expression. Am J Clin Pathol. 2015 Mar;143(3):451-8.
Bernet L, Martinez Benaclocha M, Castera C, Cano Munoz R, Sevilla F, Alba J, et al. mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study. Diagn Mol Pathol. 2012 Jun;21(2):84-92.
Masmoudi H, Hewitt SM, Petrick N, Myers KJ, Gavrielides MA. Automated quantitative assessment of HER-2/neu immunohistochemical expression in breast cancer. IEEE Trans Med Imaging. 2009 Jun;28(6):916-25.
Minot DM, Kipp BR, Root RM, Meyer RG, Reynolds CA, Nassar A, et al. Automated cellular imaging system III for assessing HER2 status in breast cancer specimens: development of a standardized scoring method that correlates with FISH. Am J Clin Pathol. 2009 Jul;132(1):133-8.
Slodkowska J, Filas V, Buszkiewicz E, Trzeciak P, Wojciechowski M, Koktysz R, et al. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio). Folia Histochem Cytobiol. 2010 Jan 1;48(1):19-25.
Minot DM, Voss J, Rademacher S, Lwin T, Orsulak J, Caron B, et al. Image analysis of HER2 immunohistochemical staining. Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique. Am J Clin Pathol. 2012 Feb;137(2):270-6.
Helin HO, Tuominen VJ, Ylinen O, Helin HJ, Isola J. Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry. Virchows Arch. 2016 Feb;468(2):191-8.
Umemura S, Osamura RY, Akiyama F, Honma K, Kurosumi M, Sasano H, et al. What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard. Am J Clin Pathol. 2008 Dec;130(6):883-91.
Wasielewski R, Hasselmann S, Ruschoff J, Fisseler-Eckhoff A, Kreipe H. Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Arch. 2008 Dec;453(6):537-43.
Staradub VL, Messenger KA, Hao N, Wiley EL, Morrow M. Changes in breast cancer therapy because of pathology second opinions. Ann Surg Oncol. 2002 Dec;9(10):982-7.
Manion E, Cohen MB, Weydert J. Mandatory second opinion in surgical pathology referral material: clinical consequences of major disagreements. Am J Surg Pathol. 2008 May;32(5):732-7.
Castera C. Bernet L. Growing up together. HER2 equivocal cases and clinical guidelines. Rev. Esp. Pat. July – Sept 2017; 50(3): 142-147.
Palacios Calvo J, Albanell J, Rojo F, Ciruelos E, Aranda-Lopez I, Cortes J, et al. Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Rev Esp Patol. 2018 Apr – Jun;51(2):97-109.
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382.
Casterá C, Bernet L. HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH. Ann Diagn Pathol. 2020 Apr;45:151451.
Kennedy, Sean P et al. “The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family.” Frontiers in cell and developmental biology vol. 4 88. 22 Aug. 2016